Phase 1 Schizophrenia Trial, Recruiting NCT04038840 Sponsor: Davidzon, Guido, M.D. Condition: Schizophrenia
Back to Schizophrenia

Phase 1 Schizophrenia Trial, Recruiting

NCT04038840
Recruiting Phase 1

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People between 18 and 65 years of age
  • For people with schizophrenia: those who have been on a stable medication routine for at least two weeks before the study visit
  • For people with schizophrenia: those with a diagnosed schizophrenia, schizophreniform disorder, or schizoaffective disorder
  • For people with schizophrenia: those who are able to complete a PET-MR brain scan without needing sedation

Who may not be able to join:

  • People who have used substances (such as drugs or alcohol) in the three months before testing
  • People with an IQ below 70
  • People with a serious neurological illness or significant head injury
  • People who are pregnant or breastfeeding
  • People who cannot safely have an MRI scan — for example, those with metal implants, pacemakers, cochlear implants, or bullets near a vital organ
  • People who weigh more than 350 lbs, or whose body size cannot be accommodated by the MRI scanner
  • People who have had, or currently experience, claustrophobia (fear of enclosed spaces)
  • People who are unable to follow basic study requirements, such as following instructions and arriving on time
  • For healthy volunteers (people without schizophrenia): those who have a parent, sibling, or child with a psychotic disorder
  • For healthy volunteers: those with a lifetime diagnosis of a major psychiatric illness
  • For people with schizophrenia: those experiencing unstable psychiatric symptoms at the time of testing, such as active thoughts of suicide, severe psychosis, or difficulty controlling behaviour

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 23 July 2026
Phase 1: approximately ~10% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Jong H Yoon, MD, Stanford University

Phone: 650-849-0552

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 1
Sponsor
Davidzon, Guido, M.D.
Registry
ClinicalTrials.gov
Start date
1 August 2019
Est. completion
1 December 2025

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Cross-sectional differences in synaptic density between HC and SZ participants

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 23 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov